Advances in Cancer Immunotherapy for Solid Tumors.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and clinical developments without systematic methodology
PubMed 42261754 · doi:10.1002/advs.76020
What was done
This narrative review summarizes recent advances in cancer immunotherapy for solid tumors beyond conventional CTLA-4 and PD-1/PD-L1 blockade. It surveys novel immune checkpoints, biomarker-guided indications, antibody-based platforms, adoptive cellular therapies, next-generation cytokines, cancer vaccines, and clinical trial design considerations.
What was found
The abstract provides a descriptive overview of emerging therapeutic platforms and mechanistic concepts; it reports no quantitative data, response rates, survival statistics, or numerical findings.
Why it matters
It outlines strategies being developed to overcome resistance, mitigate toxicities, and expand immunotherapy efficacy across diverse solid malignancies.
Limits
The abstract reports no empirical data or quantitative metrics. As a narrative review, it lacks a systematic literature search, formal study selection criteria, and meta-analytic synthesis.
Cited by
- supports Immune checkpoint inhibitor therapies targeting PD-1 and CTLA-4 block natural inhibitory receptors on T cells to enhance anti-tumor immune responses.